The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv), a therapy designed to delay the onset of stage 3 type 1 diabetes (T1D). The application seeks to expand the current age indication from patients aged eight years and older to include children as young as one year old who have been diagnosed with stage 2 T1D. If approved, the expanded indication could significantly broaden access to the therapy for very young patients at high risk of progressing to clinical diabetes.
The sBLA is supported by positive interim one-year data from the ongoing PETITE-T1D Phase 4 study, which is evaluating the safety and pharmacokinetics of Tzield in young children. The study, registered under clinical study identifier NCT05757713, focuses on understanding how the therapy performs in a pediatric population where the autoimmune processes underlying T1D often begin early in life. The FDA has set a target action date of April 29, 2026, for its regulatory decision.
Tzield is an immunomodulatory therapy intended to delay the destruction of insulin-producing beta cells by targeting the autoimmune response that drives type 1 diabetes. It was previously approved for delaying the onset of stage 3 T1D in patients aged eight years and older with stage 2 disease. Expanding its use to younger children could represent an important step toward earlier intervention, potentially preserving endogenous insulin production for a longer period.
Christopher Corsico, Global Head of Development at Sanofi, emphasized the importance of the FDA’s decision to grant priority review. He noted that the designation highlights the urgent need for innovative therapies capable of altering the natural course of type 1 diabetes, particularly in very young patients. According to Corsico, early intervention may be especially meaningful because the autoimmune attack that leads to T1D often starts in early childhood. Delaying progression to stage 3 disease could reduce both the clinical burden on patients and the emotional and logistical challenges faced by caregivers.
Interim data from the PETITE-T1D study were presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes and were simultaneously published in the peer-reviewed journal Diabetologia. These data contributed to the FDA’s decision to grant priority review, a regulatory pathway reserved for therapies that may offer significant improvements in the treatment, diagnosis, or prevention of serious conditions.
While the acceptance of the sBLA marks an important regulatory milestone, the safety and efficacy of Tzield in the PETITE-T1D pediatric population have not yet been approved by any regulatory authority. The FDA’s final decision will determine whether the therapy can be made available to younger children, potentially reshaping the early management of type 1 diabetes.